Purpose of this Study
We are doing this study to find out if an experimental drug called BMS-986322 (the study drug) is a safe and effective option for people with moderate to severe psoriasis.
Who Can Participate?
Eligibility
Adults ages 18-70 who:
- Have been diagnosed with psoriasis for at least 6 months
- Are not pregnant or breastfeeding
For more information about who can join this study, please contact the study team at erin.campo@duke.edu.
- Have been diagnosed with psoriasis for at least 6 months
- Are not pregnant or breastfeeding
For more information about who can join this study, please contact the study team at erin.campo@duke.edu.
Age Range
18-70
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
This is a 12-week, double-blind study that is divided into 3 separate periods: a screening period, a study drug treatment period, and a safety follow-up period. Double-blind means that neither you nor your study doctor will know if you will be receiving the study drug or placebo (inactive substance that has no drug in it).
If you decide to take part in this study, the screening period will last up to 4 weeks and you will have the following tests and procedures:
- A physical exam
- Questionnaires
- Blood draws
- ECG (a test to measure your heart rhythm and activity)
- A chest x-ray (if you have not had one in the last 6 months)
If you are eligible to join, you will be assigned randomly (by chance, like flipping a coin) to get either the study drug or placebo. The study drug period will last up to 85 days and you will take the study drug or placebo every day.
The follow-up period will start the day after your last dose of the study drug or placebo and will last up to 30 days. During this time, you will have:
- A physical exam
- Blood draws
- Pictures taken of your skin
If you decide to take part in this study, the screening period will last up to 4 weeks and you will have the following tests and procedures:
- A physical exam
- Questionnaires
- Blood draws
- ECG (a test to measure your heart rhythm and activity)
- A chest x-ray (if you have not had one in the last 6 months)
If you are eligible to join, you will be assigned randomly (by chance, like flipping a coin) to get either the study drug or placebo. The study drug period will last up to 85 days and you will take the study drug or placebo every day.
The follow-up period will start the day after your last dose of the study drug or placebo and will last up to 30 days. During this time, you will have:
- A physical exam
- Blood draws
- Pictures taken of your skin
Locations
Other
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
Multiple Dose Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986322 in Participants with Moderate-to-Severe Psoriasis
Principal Investigator
John
Murray
Protocol Number
PRO00113498
NCT ID
NCT05730725
Phase
II
Enrollment Status
OPEN TO ACCRUAL